These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 14755376)

  • 1. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.
    Rick ME; Austin H; Leitman SF; Krizek DM; Aronson DL
    Am J Hematol; 2004 Feb; 75(2):96-100. PubMed ID: 14755376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A woman suffering from systemic lupus erythematosus and acquired thrombotic thrombocytopenic purpura].
    Verheijen FM; Reedijk L; Fijnheer R
    Ned Tijdschr Geneeskd; 2004 Oct; 148(40):1977-81. PubMed ID: 15524134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
    Furlan M; Lämmle B
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
    N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
    Furlan M
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):243-55. PubMed ID: 15030284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
    Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
    Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
    Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
    Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
    Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I
    Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activity loss of Von Willebrand factor cleaving protein (ADAMTS-13) is diagnostic for primary and pregnancy-related thrombotic thrombocytopenic purpura].
    Hulstein JJ; Rison CN; Kappers-Klunne MC; Hene RJ; Franx A; de Groot PG; Brand A; Fijnheer R
    Ned Tijdschr Geneeskd; 2004 Oct; 148(40):1972-6. PubMed ID: 15524133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
    Tsai HM; Lian EC
    N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
    Furlan M; Robles R; Solenthaler M; Lämmle B
    Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features and laboratory findings of thrombotic thrombocytopenic purpura associated with ticlopidine].
    Yagi H
    Rinsho Byori; 2005 Jul; 53(7):630-8. PubMed ID: 16104532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13.
    Kostousov V; Fehr J; Bombeli T
    Thromb Res; 2006; 118(6):723-31. PubMed ID: 16430944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
    Moake JL
    Semin Hematol; 2004 Jan; 41(1):4-14. PubMed ID: 14727254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADAMTS-13 may not predict disease or outcome in patients with Thrombotic Thrombocytopenic Purpura.
    Rock G; Clark WF; Anderson D; Benny B; Sutton D; Leblond P; Sternbach M; Sontrop J;
    Thromb Res; 2013 Apr; 131(4):308-12. PubMed ID: 23411128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
    Tsai HM
    J Am Soc Nephrol; 2003 Apr; 14(4):1072-81. PubMed ID: 12660343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13).
    Böhm M; Vigh T; Scharrer I
    Ann Hematol; 2002 Aug; 81(8):430-5. PubMed ID: 12223999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of von Willebrand protease in aetiopathogenesis of thrombotic thrombocytopenic purpura].
    Suvajdzić-Vuković N
    Srp Arh Celok Lek; 2007; 135(5-6):360-6. PubMed ID: 17633329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).
    Mannucci PM; Vanoli M; Forza I; Canciani MT; Scorza R
    Haematologica; 2003 Aug; 88(8):914-8. PubMed ID: 12935979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.